Leone Patterson is a seasoned executive with over two decades of experience in the biopharmaceutical industry, specializing in finance, business development, and strategic leadership. She began her career at a leading global pharmaceutical firm, where she honed her skills in financial planning and analysis, eventually rising to senior roles in corporate finance. Patterson holds a Bachelor's degree in Accounting from the University of Toronto and an MBA from Harvard Business School, which equipped her with a strong foundation in both technical expertise and strategic acumen. Prior to joining Zymeworks Inc., she served as Chief Financial Officer at a mid-cap biotech company, where she successfully navigated complex mergers and acquisitions, securing significant funding rounds that propelled innovative drug development pipelines. Throughout her career, Patterson has been recognized for her pivotal contributions to financial restructuring and growth initiatives. She led a high-profile turnaround effort at her previous company, resulting in a 150% increase in market capitalization within three years through optimized resource allocation and strategic partnerships. Her achievements include negotiating multimillion-dollar licensing agreements with major pharmaceutical players, enhancing revenue streams and expanding global reach. Patterson is also an advocate for diversity in STEM fields, serving on boards of several nonprofit organizations focused on women in science and technology, and she has been honored with awards such as the CFO of the Year by Biotech Finance Magazine in 2020. In her current role as Executive Vice President, Chief Business Officer, and Chief Financial Officer at Zymeworks Inc., Patterson oversees the company's financial operations, business development strategies, and corporate partnerships. She plays a critical role in advancing Zymeworks' mission to develop novel multispecific antibody therapeutics for cancer treatment, ensuring fiscal discipline while driving innovation. Under her leadership, the company has strengthened its balance sheet, forged key collaborations with industry leaders, and positioned itself for sustained growth in the competitive oncology market.